Biopharmaceutical companies have announced an abundance of investment in their companies from US government sources recently, which adds to the flurry of new investment funds backing drug developers, including the new €360m ($415.9m) venture capital fund revealed by Forbion on Oct. 1.
Forbion joins Hillhouse Capital, which closed a $10.6bn private equity fund in September to invest across several industries, including health...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?